PRPO logo.png
New York State Approves Precipio’s HemeScreen for POL clinical use
November 18, 2021 10:00 ET | Precipio, Inc.
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from...
PRPO logo.png
American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory
August 26, 2021 10:00 ET | Precipio, Inc.
NEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), and American Oncology Network, LLC (AON), a high-growth...
PRPO logo.png
Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool
June 08, 2021 10:30 ET | Precipio, Inc.
 Laboratories can use this rapid, cost effective test to distinguish malignancy-driven anemia from other causes NEW HAVEN, Conn., June 08, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company...
PRPO logo.png
Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time
May 10, 2021 10:30 ET | Precipio, Inc.
NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has launched a new, four-hour Acute Myeloid Leukemia (AML)...
PRPO logo.png
Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio’s HemeScreen POL Offering by Q4-2021
April 26, 2021 11:00 ET | Precipio, Inc.
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that currently, the contracted annualized revenues from signed customers...
PRPO logo.png
Mr. Ron Andrews joins Precipio’s Board of Directors
March 03, 2021 13:00 ET | Precipio, Inc.
NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that Mr. Ron Andrews has joined the company’s Board of Directors. As...
PRPO logo.png
Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups
January 20, 2021 10:00 ET | Precipio, Inc.
NEW HAVEN, Conn., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has signed agreements with two of the largest oncology practices in the US,...
PRPO logo.png
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
December 10, 2020 10:15 ET | Precipio, Inc.
NEW HAVEN, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with a major US-based oncology distributor to...
PRPO logo.png
Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
September 22, 2020 10:30 ET | Precipio, Inc.
NEW HAVEN, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ AML (Acute Myeloid...
PRPO logo.png
Precipio Adds Another HemeScreen™ Customer
June 09, 2020 10:00 ET | Precipio, Inc.
NEW HAVEN, Conn., June 09, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Cancer and Hematology Centers of Western Michigan (CHCWM) has adopted...